312 related articles for article (PubMed ID: 27354579)
1. Current Status of Biological Therapies for the Treatment of Metastatic Melanoma.
Tang T; Eldabaje R; Yang L
Anticancer Res; 2016 Jul; 36(7):3229-41. PubMed ID: 27354579
[TBL] [Abstract][Full Text] [Related]
2. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
[TBL] [Abstract][Full Text] [Related]
3. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.
Azijli K; Stelloo E; Peters GJ; VAN DEN Eertwegh AJ
Anticancer Res; 2014 Apr; 34(4):1493-505. PubMed ID: 24692676
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists.
Kakavand H; Wilmott JS; Long GV; Scolyer RA
Pathology; 2016 Feb; 48(2):194-202. PubMed ID: 27020392
[TBL] [Abstract][Full Text] [Related]
5. Molecular genetic and immunotherapeutic targets in metastatic melanoma.
Melis C; Rogiers A; Bechter O; van den Oord JJ
Virchows Arch; 2017 Aug; 471(2):281-293. PubMed ID: 28357489
[TBL] [Abstract][Full Text] [Related]
6. A review of novel therapies for melanoma.
Karimkhani C; Gonzalez R; Dellavalle RP
Am J Clin Dermatol; 2014 Aug; 15(4):323-37. PubMed ID: 24928310
[TBL] [Abstract][Full Text] [Related]
7. Gaining momentum: New options and opportunities for the treatment of advanced melanoma.
Michielin O; Hoeller C
Cancer Treat Rev; 2015 Sep; 41(8):660-70. PubMed ID: 26096079
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Advances and Treatment Options in Metastatic Melanoma.
Johnson DB; Sosman JA
JAMA Oncol; 2015 Jun; 1(3):380-6. PubMed ID: 26181188
[TBL] [Abstract][Full Text] [Related]
9. New drugs in melanoma: it's a whole new world.
Eggermont AM; Robert C
Eur J Cancer; 2011 Sep; 47(14):2150-7. PubMed ID: 21802280
[TBL] [Abstract][Full Text] [Related]
10. BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro.
Gargett T; Fraser CK; Dotti G; Yvon ES; Brown MP
J Immunother; 2015 Jan; 38(1):12-23. PubMed ID: 25415284
[TBL] [Abstract][Full Text] [Related]
11. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
12. Beyond CTLA-4: novel immunotherapy strategies for metastatic melanoma.
Matikas A; Mavroudis D
Future Oncol; 2015; 11(6):997-1009. PubMed ID: 25760979
[TBL] [Abstract][Full Text] [Related]
13. Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges.
Millet A; Martin AR; Ronco C; Rocchi S; Benhida R
Med Res Rev; 2017 Jan; 37(1):98-148. PubMed ID: 27569556
[TBL] [Abstract][Full Text] [Related]
14. Metastatic melanoma treatment: Combining old and new therapies.
Davey RJ; van der Westhuizen A; Bowden NA
Crit Rev Oncol Hematol; 2016 Feb; 98():242-53. PubMed ID: 26616525
[TBL] [Abstract][Full Text] [Related]
15. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma.
Agarwala SS
Melanoma Res; 2010 Feb; 20(1):1-10. PubMed ID: 19952852
[TBL] [Abstract][Full Text] [Related]
16. Targeted agents and immunotherapies: optimizing outcomes in melanoma.
Luke JJ; Flaherty KT; Ribas A; Long GV
Nat Rev Clin Oncol; 2017 Aug; 14(8):463-482. PubMed ID: 28374786
[TBL] [Abstract][Full Text] [Related]
17. Targeting oncogenic drivers and the immune system in melanoma.
McArthur GA; Ribas A
J Clin Oncol; 2013 Feb; 31(4):499-506. PubMed ID: 23248252
[TBL] [Abstract][Full Text] [Related]
18. Emerging Strategies in Systemic Therapy for the Treatment of Melanoma.
Ascierto PA; Flaherty K; Goff S
Am Soc Clin Oncol Educ Book; 2018 May; 38():751-758. PubMed ID: 30231371
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of Melanoma.
Snyder A; Zamarin D; Wolchok JD
Prog Tumor Res; 2015; 42():22-9. PubMed ID: 26376963
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]